Disease · MONDO_0004981
Comparisons in its trials162
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 162
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dabigatran 110 mg vs Dabigatran 150 mg: serious adverse events | 1,028 of 2,914 | 1,106 of 2,937 | 5,851 | NCT00808067 | Trial comparisons |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Systemic Embolism Event | 0 of 753 | 0 of 747 | 1,500 | NCT02100228 | Trial comparisons |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Acute Stroke Event | 0 of 753 | 6 of 747 | 1,500 | NCT02100228 | Trial comparisons |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With All Cause Death | 2 of 753 | 1 of 747 | 1,500 | NCT02100228 | Trial comparisons |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants Who Used Image Guidance Approach | 383 of 753 | 399 of 747 | 1,500 | NCT02100228 | Trial comparisons |
| Edoxaban Regimen vs Vitamin K Antagonist Regimen: deaths from any cause | 46 of 746 | 37 of 740 | 1,486 | NCT02866175 | Trial comparisons |
| Edoxaban Regimen vs Vitamin K Antagonist Regimen: serious adverse events | 176 of 746 | 175 of 740 | 1,486 | NCT02866175 | Trial comparisons |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Major Bleeding Event | 3 of 735 | 6 of 721 | 1,456 | NCT02100228 | Trial comparisons |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): deaths from any cause | 1 of 735 | 3 of 721 | 1,456 | NCT02100228 | Trial comparisons |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Clinically Relevant Non-Major Bleeding Events | 11 of 735 | 13 of 721 | 1,456 | NCT02100228 | Trial comparisons |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): serious adverse events | 100 of 735 | 112 of 721 | 1,456 | NCT02100228 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Bleeding (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA | 98 of 713 | 68 of 713 | 1,426 | NCT02943785 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Myocardial Infarctions (MI) in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 12 of 713 | 7 of 713 | 1,426 | NCT02943785 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Adverse Cardiac Events (MACE) in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 61 of 713 | 53 of 713 | 1,426 | NCT02943785 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Adverse Cardiac and Cerebrovascular Events (MACCE) in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 86 of 713 | 80 of 713 | 1,426 | NCT02943785 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Systemic Embolic Events in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 2 of 713 | 3 of 713 | 1,426 | NCT02943785 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Valve Thrombosis in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 0 of 713 | 0 of 713 | 1,426 | NCT02943785 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA | 170 of 713 | 157 of 713 | 1,426 | NCT02943785 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced a Composite of Adverse Events in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 151 of 713 | 123 of 713 | 1,426 | NCT02943785 | Trial comparisons |
| Edoxaban vs Vitamin K Antagonist (VKA): deaths from any cause | 83 of 693 | 78 of 684 | 1,377 | NCT02943785 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004981/comparisons